Jeff Yass’s CervoMed CRVO Stock Holding History

Jeff Yass’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,075	Closed	-$82.2K	–	12601
2025 Q2	$82.2K	Buy	+13,075	New	+$111K	﹤0.01%	11899
2021 Q1	–	Sell	-292	Closed	-$17K	–	12306
2020 Q4	$17K	Buy	292 +90	+45%	+$5.27K	﹤0.01%	10895
2020 Q3	$13K	Buy	+202	New	+$15.4K	﹤0.01%	10403
2020 Q2	–	Sell	-154	Closed	-$4K	–	10208
2020 Q1	$4K	Buy	+154	New	+$4.67K	﹤0.01%	10114

Other funds holding CRVO

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Jeff Yass's CRVO Position: Q3 2025 in Review

Jeff Yass sold out of CervoMed (CRVO) in Q3 2025, closing a stake of 13,075 shares — an estimated $82.2K sold.

Jeff Yass first reported a position in CRVO in Q1 2020 and held it in 4 quarters. The position peaked at $82.2K in Q2 2025. 45 funds tracked by Wall St. Rank hold CRVO as of Q3 2025.

Jeff Yass reported no remaining CervoMed position as of Q3 2025 after selling out during the quarter.
Jeff Yass sold 13,075 CervoMed shares in Q3 2025, an estimated $82.2K.
Jeff Yass first reported a position in CervoMed in Q1 2020 and held it in 4 quarters.
Jeff Yass's CervoMed position peaked at $82.2K in Q2 2025.
45 funds tracked by Wall St. Rank held CervoMed as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.